4.8 Article

Drug delivery with carbon nanotubes for in vivo cancer treatment

Journal

CANCER RESEARCH
Volume 68, Issue 16, Pages 6652-6660

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-08-1468

Keywords

-

Categories

Funding

  1. NIH-National Cancer Institute Center for Cancer Nanotechnology Excellence Focused on Therapeutic Response at Stanford
  2. Stanford Bio-X Initiative
  3. NIH-National Cancer Institute [CA135109-01]
  4. Stanford Graduate

Ask authors/readers for more resources

Chemically functionalized single-walled carbon nanotubes (SWNT) have shown promise in tumor-targeted accumulation in mice and exhibit biocompatibility, excretion, and little toxicity. Here, we show in vivo SWNT drug delivery for tumor suppression in mice. We conjugate paclitaxel (PTX), a widely used cancer chemotherapy drug, to branched polyethylene glycol chains on SWNTs via a cleavable ester bond to obtain a water-soluble SWNT-PTX conjugate. SWNT-PTX affords higher efficacy in suppressing tumor growth than clinical Taxol in a murine 4T1 breast cancer model, owing to prolonged blood circulation and 10-fold higher tumor PTX uptake by SWNT delivery likely through enhanced permeability and retention. Drug molecules carried into the reticuloendothelial. path-system are released from SWNTs and excreted via biliary way without causing obvious toxic effects to normal organs. Thus, nanotube drug delivery, is promising for high treatment efficacy and minimum side effects for future cancer therapy with low drug doses.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available